Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Royal Bank Of Canada from a "sector perform" rating to an "outperform" rating.
Neumora Therapeutics (NASDAQ:NMRA) had its price target raised by analysts at Stifel Nicolaus from $2.00 to $3.00. They now have a "hold" rating on the stock.
Neumora Therapeutics GAAP EPS of -$0.35 misses by $0.02 [Seeking Alpha]
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Neumora Therapeutics to Participate in Upcoming Conferences in November